Deutsche Bank's research report on Gilead Sciences discusses the voluntary recall of Atripla due to small particles found during a quality check. The recall involves 39,000 bottles from a third-party manufacturer in China. Gilead has multiple manufacturers and sufficient supply of Atripla. The report reiterates a 'Buy' rating with a price target of $132, despite the recall. Key financial data and stock information are provided.
doj/DataSet10/EFTA01453077.pdf
{"title":"Deutsche Bank Markets Research - Gilead Sciences Alert","key_people":["Robyn Kamauskas","Alethia Young"],"document_date":"2014-03-06","document_type":"tabular","key_locations":["United States","China"],"document_subtype":"financial report","key_organizations":["Deutsche Bank","Gilead Sciences","FDA"],"reference_numbers":["D-1090-2014"]}